Trial · NCT01402440
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
NCT01402440, Phase 1, Terminated, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma. Trials, record NCT01402440. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01402440
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
- NCT number
- NCT01402440
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 15 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- AEB071
- First posted
- 2011-07-26
- Last updated
- 2020-12-19
- Other registries' IDs
- eudract:2010-024367-41
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frequency of Dose Limiting Toxicity (DLT) during cycle 1 (Dose Escalation phase) | Cycle 1 (28 days) | |
| Primary | Number of Pparticipants reporting Serious Adverse Events and Adverse Events (Dose Expansion phase) | Baseline, 28 days | |
| Secondary | Overall Response Rate, using NHLIWG criteria | Baseline, 12 months | Assess the overall response rate to AEB071 |
| Secondary | Number of Participants reporting Serious Adverse Events and Adverse Events | Baseline, 12 months | |
| Secondary | AEB071 PK parameters including Cmax, tmax, AUCt, Ctrough, CL/F and RA | First 7 months of treatment period | Evaluate the single and multiple dose PK of AEB071 in patients with Diffuse Large B-Cell Lymphoma (DLBCL) |
| Secondary | Pre and post-dose gene and protein expression of cytokines and any correlations with exposure to AEB071 | First 7 months of treatment period | Assess the pharmacodynamic response to AEB071 in Lymphoma and blood specimens |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01402440
GET https://conductscience.org/api/trials/v1/NCT01402440/registered